Dr. Emad Kandil Achieves Milestone of 100 Microwave Ablation Cases in Thyroid Care

Rhea-AI Summary

Baird Medical Investment Holdings (NASDAQ: BDMD) announced that Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, has completed 100 Microwave Ablation (MWA) procedures for thyroid nodules. This milestone demonstrates the increasing adoption of MWA technology in thyroid treatment.

Dr. Kandil's achievement highlights MWA as a safe and effective alternative to traditional thyroid surgery, offering benefits such as faster recovery times, reduced procedural risks, and improved quality of life. Baird Medical presented Dr. Kandil with a Certificate of Excellence for his contributions to advancing thyroid care.

The company reaffirmed its commitment to advancing MWA technology through continued collaboration with physicians and investment in medical education.

Positive

• Growing adoption of MWA technology in thyroid treatment demonstrated by 100 successful procedures
• Clinical validation of MWA technology by leading medical professional

Negative

• None.

Insights

Medical Research Analyst

The achievement of 100 successful Microwave Ablation procedures by Dr. Kandil represents a positive clinical validation data point, but lacks material financial impact for investors to act upon. While the milestone demonstrates growing adoption of MWA technology and clinical acceptance, this news primarily serves as a marketing announcement rather than a market-moving catalyst.

The real value lies in the broader implications: MWA procedures typically generate $3,000-5,000 in revenue per case. With an estimated 600,000 thyroid procedures performed annually in the US, even capturing 5% of this market could represent significant revenue potential. However, this particular announcement doesn't provide concrete metrics about market penetration rates, procedure volumes, or revenue projections that would substantively impact valuation models.

For a company with a $316M market cap, individual physician milestones, while encouraging for clinical adoption, don't materially move the needle on financial projections or stock valuation. Investors should focus more on quarterly procedure volumes, reimbursement developments and competitive positioning in the broader minimally invasive surgery market.

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in minimally invasive Microwave Ablation (MWA) technology, proudly announces that Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, has reached a remarkable milestone of successfully completing 100 MWA procedures for thyroid nodules. This achievement underscores both the growing adoption of MWA and the transformative potential of the technology in treating thyroid conditions.

Dr. Kandil, a pioneering expert in thyroid surgery and minimally invasive techniques, has been instrumental in advancing MWA as a safe and effective alternative to traditional thyroid surgery. His completion of 100 cases highlights the precision, efficiency, and clinical value of MWA, offering patients faster recovery times, reduced procedural risks, and improved quality of life.

To honor this achievement, Baird Medical presented Dr. Kandil with a Certificate of Excellence, recognizing his leadership in advancing thyroid care and his dedication to adopting cutting-edge solutions for better patient outcomes.

As MWA technology continues to evolve, Baird Medical is committed to driving innovation and expanding access to advanced thyroid care. Through ongoing collaboration with leading physicians and investment in physician education, Baird aims to deliver even greater value to the medical community and the patients they serve.

About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/dr-emad-kandil-achieves-milestone-of-100-microwave-ablation-cases-in-thyroid-care-302355874.html

SOURCE BDMD

FAQ

What milestone did Dr. Kandil achieve with BDMD's Microwave Ablation technology?

Dr. Emad Kandil completed 100 successful Microwave Ablation (MWA) procedures for thyroid nodules, demonstrating the growing adoption and effectiveness of this minimally invasive technology.

What are the benefits of BDMD's Microwave Ablation technology for thyroid treatment?

BDMD's MWA technology offers faster recovery times, reduced procedural risks, and improved quality of life compared to traditional thyroid surgery.

How is BDMD planning to expand its Microwave Ablation technology adoption?

BDMD is focusing on collaboration with leading physicians and investing in physician education to expand access to advanced thyroid care.

What recognition did BDMD give to Dr. Kandil for his achievement?

BDMD presented Dr. Kandil with a Certificate of Excellence for his leadership in advancing thyroid care and dedication to adopting cutting-edge solutions.